Half of surveyed physicians expect to replace between 6 percent and 15 percent of their Sustiva prescriptions with Isentress
Most surveyed MCO pharmacy directors do not place cost control measures on branded antiretroviral drugs, according to a new report from Decision Resources

BAXTER ANNOUNCES LICENSING AGREEMENT FOR INNOCOLL’S GENTAMICIN SURGICAL IMPLANT IN THE UNITED STATES
BAXTER ANNOUNCES LICENSING AGREEMENT FOR INNOCOLL’S GENTAMICIN SURGICAL IMPLANT IN THE UNITED STATES

PharmiGene receives regulatory approval for test assessing risk of adverse drug reaction to Carbamazepine
Pharmacogenomics-based diagnostics test identifying patients with greater risk of Carbamazepine-induced adverse drug reaction is world's first, and a milestone towards personalized medicine.

Pharmacogenomics-based drug development holds promise
Personalized medicine has the potential for good and bad,

India’s hepatitis b virus drug market will grow ten-fold by 2012
Physician treatment patterns and drivers will vary based on drug’s safety, efficacy and cost. - Decision Resources expands Emerging Markets report series to include India

Relative to their population size, New England states should support largest markets for dyslipidemia drugs
Massachusetts, Maine and Vermont have the highest percentages of dyslipidemia patients who have prescription drug coverage but are currently untreated, according to a new analytics tool from Decision Resources

Launches of Humira, Golimumab and Orencia for treatment of ulcerative colitis will drive annual five percent market growth
Expected approvals of biologic agents will expand treatment options for patients who fail conventional drug treatment, according to a new report from Decision Resources

Insulin analogues from Novo Nordisk, Eli Lilly and Sanofi-Aventis will drive growth in the type 1 diabetes drug market
Owing to well-established and effective insulin-based therapies, market growth will be modest through 2017, according to a new report from Decision Resources

Astonishing 52 percent of newly diagnosed bipolar disorder patients receive antidepressant drugs in first-line treatment
Lamictal is the leading single-agent in first-, second- and third-line therapy, according to a new report from Decision Resources

Florida is the state with the highest number of type 2 diabetics who have prescription drug coverage but are currently untreated
Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated

Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

Swedish Skin Care's technology receives patent protection in Canada, extending the Company's licensing territory throughout North America
Swedish Skin Care's patented licensing opportunities expand throughout North America with new Canadian Patent

Eighty-nine percent of surveyed rheumatologists say they will prescribe Roche/Chugai’s Actemra for Rheumatoid Arthritis
However, pharmacy directors disagree about formulary inclusion for key emerging biologic agents that will launch for the disease in the next few years, according to a new report from Decision Resources

Sales of emerging novel pain therapies will represent more than one-fifth of the total pain drug market by 2023
Total drug market for pain will reach more than US$47 billion in 2023, according to a new report from Decision Resources

Ondansetron RapidFilm™ licensed to BioAlliance Pharma for Europe
A new innovative product near registration filing in cancer supportive care

APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, announce the signature of an exclusive licensing agreement with BioAlliance Pharma SA. for Ondansetron RapidFilm
APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, announce the signature of an exclusive licensing agreement with BioAlliance Pharma SA. for Ondansetron RapidFilm™ for Europe

A high-density lipoprotein raising drug that has a lower discontinuation rate than that of extended release Niaspan would earn a 20 percent patient share in the Dyslipidemia drug market
Crestor will remain the clinical gold standard drug through 2016, according to a new report from Decision Resources

Innocoll Announces Dosing of First Patient in a Third US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
Innocoll Announces Dosing of First Patient in a Third US Phase 2 Clinical Trial to Investigate CollaRx® BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain

Lori Silver joins Decision Resources, Inc. as General Counsel
Formerly of Harvard University’s office of General Counsel, attorney will be responsible for all legal aspects of the company

A drug that improves exercise capacity by a greater percentage than Tracleer would earn a 48 percent patient share in the Pulmonary Arterial Hypertension market
Gleevec will achieve clinical gold standard status by 2011, according to a new report from Decision Resources